Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

G-protein Coupled Receptors

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:

Depressive Disorders: Etiology

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Normalization of Gastrointestinal Symptoms in Adults With Constipation With Daily Green Kiwifruit Consumption: Protocol for an Open-Label Intervention Study.

JMIR research protocols·2026

Same author

Clinical Characteristics and Outcomes of Rome IV Diarrhea-Predominant Irritable Bowel Syndrome and Functional Diarrhea Prescribed With Ondansetron: A Real-World Study.

Neurogastroenterology and motility·2025

Same author

Assessing Water Content of the Human Colonic Chyme Using the MRI Parameter T1: A Key Biomarker of Colonic Function.

Neurogastroenterology and motility·2025

Same author

Magnetic Resonance Imaging Reveals Novel Insights into the Dual Mode of Action of Bisacodyl: A Randomized, Placebo-controlled Trial in Constipation.

Clinical pharmacology and therapeutics·2024

Same author

Editorial: Emulsifiers and thickeners in our food-Do they alter gut permeability?

Alimentary pharmacology & therapeutics·2024

Same author

A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes: a pilot study.

NIHR open research·2024

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Serotonin and GI clinical disorders.

Robin Spiller¹

¹Wolfson Digestive Diseases Centre, C Floor South Block, University Hospital, Clifton Boulevard, Nottingham, NG7 2UH, United Kingdom. robin.spiller@nottingham.ac.uk

Neuropharmacology

|August 9, 2008

Summary

This summary is machine-generated.

Serotonin, a key gut signaling molecule, plays a role in various gastrointestinal functions and disorders. Understanding its release and receptor interactions is crucial for treating conditions like irritable bowel syndrome and chemotherapy-induced nausea.

Related Experiment Videos

Last Updated: Jul 3, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Area of Science:

Gastroenterology
Neurogastroenterology
Pharmacology

Background:

Serotonin (5-HT) is abundant in the gut, produced by enteric nerves and enterochromaffin (EC) cells.
EC cells function as signal transducers, releasing 5-HT in response to stimuli, influencing gut reflexes.
Inflammation impacts 5-HT levels and serotonin transporter (SERT) function, affecting gut motility and secretion.

Purpose of the Study:

To elucidate the role of serotonin in gastrointestinal function and disease.
To explore the mechanisms of 5-HT dysregulation in conditions like IBS and chemotherapy side effects.
To identify potential therapeutic targets for gastrointestinal disorders involving serotonin.

Main Methods:

Review of existing literature on serotonin's distribution and function in the gut.
Analysis of the impact of inflammation on EC cells and SERT activity.
Examination of the efficacy of serotonin receptor antagonists and agonists in clinical conditions.

Main Results:

Inflammation increases EC cell numbers and 5-HT content while decreasing SERT function.
Conditions like post-infectious IBS and IBS with diarrhea show elevated mucosal 5-HT.
5-HT(3) receptor antagonists effectively treat chemotherapy-induced nausea/vomiting and IBS-D symptoms.
5-HT(3) and 5-HT(4) receptor agonists may benefit constipation-predominant IBS (IBS-C) and other constipating disorders.

Conclusions:

Serotonin dysregulation is implicated in various gastrointestinal disorders.
Targeting specific serotonin receptors offers therapeutic potential for managing gut symptoms.
Further research into 5-HT pathways can lead to novel treatments for functional bowel diseases.